[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Al-Barrag A, Al-Shaer M, Al-Matary N, Al-Hamdani M: 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea. Clin Ophthalmol; 2010;4:801-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil for the treatment of intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and cornea.
  • OBJECTIVE: To evaluate the efficacy and risks of complications of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of corneal intraepithelial neoplasia (CIN), and conjunctival squamous cell carcinoma (SCC).
  • PARTICIPANTS: Fifteen patients with histological evidence CIN or SCC of the conjunctiva and cornea were identified by tumor biopsy.
  • METHODS: All patients clinically evident of CIN, or SCC were evaluated, with maximum 30 months of follow-up were treated with pulsed dosing of 1% 5-FU.
  • Treatment cycles were defined as four times per day for 4 days using the medication followed by 30 days without medication.
  • The number of initial treatment was six cycles.
  • Excision biopsy proved seven cases as CIN, and eight cases as locally invasive SCC.
  • Additional chemotherapy was given after the initial treatment cycles, only for one case.
  • CONCLUSIONS: Adjuvant 1% topical 5-FU appears to be effective in the prevention of recurrence of conjunctival or corneal CIN and SCC after excision biopsy.
  • It is well-tolerated and an effective method of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 2009 Aug;28(7):821-4 [19574900.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1747-54 [15350332.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Doc Ophthalmol. 1986 Dec 30;64(1):31-42 [3582100.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3 [3980172.001]
  • [Cites] Am J Ophthalmol. 1984 May;97(5):547-59 [6720832.001]
  • [Cites] Am J Ophthalmol. 1983 Mar;95(3):359-63 [6829682.001]
  • [Cites] Surv Ophthalmol. 1995 May-Jun;39(6):429-50 [7660300.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [Cites] Br J Ophthalmol. 1993 Nov;77(11):751-3 [8280698.001]
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1338-44 [9097771.001]
  • [Cites] Arch Ophthalmol. 1997 Jun;115(6):808-15 [9194740.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1600-1 [9400803.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Trans Am Ophthalmol Soc. 1976;74:154-71 [325854.001]
  • [Cites] Ophthalmologica. 1979;178(4):198-203 [481865.001]
  • [Cites] Am J Ophthalmol. 1976 Feb;81(2):198-206 [766640.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):381-3 [9439364.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Cornea. 1999 Jan;18(1):59-62 [9894938.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Arch Ophthalmol. 1999 Apr;117(4):544-5 [10206591.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] Ophthalmology. 2000 Dec;107(12):2190-5 [11097594.001]
  • [Cites] Ophthalmol Clin North Am. 2005 Mar;18(1):1-13, vii [15763187.001]
  • [Cites] Ophthalmology. 2002 Feb;109(2):249-52 [11825803.001]
  • (PMID = 20689797.001).
  • [ISSN] 1177-5483
  • [Journal-full-title] Clinical ophthalmology (Auckland, N.Z.)
  • [ISO-abbreviation] Clin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2915867
  • [Keywords] NOTNLM ; chemotherapy / fluorouracil / neoplasia / treatment cycles
  •  go-up   go-down


2. de Figueirêdo RS, de Figueirêdo ES: [Use of mitomycin C for corneal-conjunctival intraepithelial neoplasia: management options--case reports]. Arq Bras Oftalmol; 2006 May-Jun;69(3):407-11
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of mitomycin C for corneal-conjunctival intraepithelial neoplasia: management options--case reports].
  • [Transliterated title] Uso de mitomicina C em neoplasia intra-epitelial córneo-conjuntival: modalidades de abordagem--relato de casos.
  • Three cases of corneal-conjunctival intraepithelial neoplasia treated differently with mitomycin C based on clinical presentation are reported.
  • The selected patients were followed at the Department of Ophthalmology of the Casa de Saúde Santo Inácio.
  • Regression of the neoplastic lesion was observed in all cases with no recurrence detected during a follow-up time ranging from 18 to 29 months.
  • The use of mitomycin C seems to be efficient and safe for the treatment of corneal-conjunctival intraepithelial neoplasia under several approaches.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Eye Neoplasms / drug therapy. Eye Neoplasms / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936968.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


3. Khong JJ, Muecke J: Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol; 2006 Jul;90(7):819-22
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia.
  • AIM: To determine the complications associated with mitomycin C (MMC) in the treatment of ocular surface neoplasia.
  • METHODS: A retrospective and consecutive study of 100 eyes in 91 patients with ocular surface neoplasia treated with MMC in a single centre between November 1998 and January 2005.
  • Outcome measures included complications of MMC and the treatment required for these complications.
  • RESULTS: One to three 7 day cycles of topical MMC 0.04% four times a day were given to 59 eyes with localised corneal-conjunctival intraepithelial neoplasia (CIN), 19 eyes with diffuse CIN, six eyes with recurrent CIN, one eye with ocular surface squamous cell carcinoma, three eyes with primary acquired melanosis (PAM) with atypia, nine eyes with conjunctival malignant melanoma (MM), two eyes with sebaceous carcinoma with pagetoid spread, and one eye with recurrent atypical fibroxanthoma.
  • Nine patients had bilateral CIN.
  • 31 (34%) cases developed an allergic reaction to MMC and 14 (14%) eyes had epiphora secondary to punctal stenosis at a mean follow up period of 26.5 months.
  • CONCLUSION: In the largest study looking at complications of topical MMC in the treatment of ocular surface neoplasia, allergic reaction and punctal stenosis are relatively common.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Drug Hypersensitivity / etiology. Eye Neoplasms / drug therapy. Mitomycin / adverse effects
  • [MeSH-minor] Adenocarcinoma, Sebaceous / drug therapy. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / drug therapy. Humans. Lacrimal Apparatus Diseases / chemically induced. Lacrimal Duct Obstruction / chemically induced. Male. Melanoma / drug therapy. Melanosis / drug therapy. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1996 Oct;114(10):1261-4 [8859090.001]
  • [Cites] Cornea. 1996 Sep;15(5):537-40 [8862932.001]
  • [Cites] Ophthalmology. 1997 Dec;104(12):2085-93 [9400769.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):303-11 [9439356.001]
  • [Cites] Am J Ophthalmol. 1997 Sep;124(3):397-9 [9439368.001]
  • [Cites] Br J Ophthalmol. 1998 May;82(5):476-9 [9713051.001]
  • [Cites] Am J Ophthalmol. 2005 Aug;140(2):325-7 [16086962.001]
  • [Cites] Allergy. 1997 Jun;52(6):687 [9226075.001]
  • [Cites] Contact Dermatitis. 2000 Feb;42(2):74-6 [10703627.001]
  • [Cites] Arch Ophthalmol. 2000 Jul;118(7):885-91 [10900099.001]
  • [Cites] Ophthalmology. 2001 May;108(5):994-5 [11320034.001]
  • [Cites] Clin Experiment Ophthalmol. 2002 Apr;30(2):94-8 [11886411.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):285-8 [12142762.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):375-7 [12888073.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 May;19(3):216-24 [12918558.001]
  • [Cites] Am J Ophthalmol. 2003 Oct;136(4):746-7 [14516822.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):950-1 [15126170.001]
  • [Cites] Br J Ophthalmol. 2004 Nov;88(11):1422-4 [15489486.001]
  • [Cites] Br J Dermatol. 1990 Feb;122(2):217-24 [2138492.001]
  • [Cites] Ophthalmology. 1992 Nov;99(11):1647-54 [1454338.001]
  • [Cites] Am J Ophthalmol. 1994 Feb 15;117(2):164-8 [8116744.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):807-9 [16782942.001]
  • (PMID = 16672325.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  • [Other-IDs] NLM/ PMC1857172
  •  go-up   go-down


Advertisement
4. Lyall DA, Srinivasan S, Roberts F: Limbal stem cell failure secondary to advanced conjunctival squamous cell carcinoma: a clinicopathological case report. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 67-year-old man with a history of multiple myeloma (treated with chemotherapy) was referred with a left hyperaemic conjunctival lesion covering almost 360° of the limbus and extending onto the corneal surface.
  • Conjunctival biopsy revealed conjunctival intraepithelial neoplasia.
  • Initial treatment consisted of topical and intralesional injections of interferon α-2b.
  • The patient subsequently developed limbal stem cell deficiency resulting in a persistent non-healing corneal epithelial defect.
  • The corneal epithelium completely healed postoperatively and there is no evidence of tumour recurrence at 1 year follow-up.
  • This case highlights a rare case of advanced ocular surface neoplasia causing secondary limbal stem cell deficiency.
  • Medical and surgical management of ocular surface neoplasia with limbal stem cell transplantation is effective in treating such cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22121391.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027379
  •  go-up   go-down


5. Schechter BA, Schrier A, Nagler RS, Smith EF, Velasquez GE: Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Cornea; 2002 Jan;21(1):6-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
  • PURPOSE: To evaluate topical interferon alpha-2b (IFNalpha2b) as a lone therapy in the treatment of primary conjunctival and corneal intraepithelial neoplasia (CIN).
  • Seven patients from three institutions, treated between February and October 1999, with presumed primary CIN lesions (clinically diagnosed by corneal specialists) were given topical IFNalpha2b drops (1 million units/mL) four to six times daily.
  • Follow-up was performed biweekly until there was complete clinical resolution of the presumed CIN lesions.
  • RESULTS: All seven eyes had complete resolution of the presumed CIN lesions after an average of 77.0 +/- 59.2 days (range, 28-188 days).
  • Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in four (57.1%) eyes.
  • In all cases, there was total resolution of conjunctival hyperemia and follicular changes within 1 month after cessation of the medication, without additional treatment.
  • CONCLUSIONS: Topical IFNalpha2b alone may be an effective treatment of primary CIN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11805499.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


6. Karp CL, Moore JK, Rosa RH Jr: Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology; 2001 Jun;108(6):1093-8
MedlinePlus Health Information. consumer health - Corneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
  • OBJECTIVE: To evaluate the role of topical interferon alfa-2b (IFNalpha2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN).
  • PARTICIPANTS: Five patients with histologically proven CIN or recurrences of proven CIN were studied prospectively.
  • INTERVENTION: After histologic confirmation, patients were given topical recombinant IFNalpha2b (INTRON A, Schering Plough, Kenilworth, NJ) 1 million IU/ml four times a day.
  • RESULTS: All patients had complete resolution of the CIN lesion on IFNalpha2b.
  • The mean time to clinical resolution was 11.6 weeks (range, 4-22 weeks).
  • One patient had a clinical recurrence of his corneal CIN 1 year after tumor resolution.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Ophthalmic Solutions. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11382635.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


7. Papandroudis AA, Dimitrakos SA, Stangos NT: Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia. Cornea; 2002 Oct;21(7):715-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia.
  • PURPOSE: To evaluate the efficacy and safety of topical mitomycin C (MMC) for conjunctival-corneal intraepithelial neoplasia (CCIN).
  • The size of the CCIN before and after the treatment and ophthalmic mitomycin C related complications were evaluated.
  • The complications of mitomycin C included a mild tearing and a slight conjunctival hyperemia that resolved 7 days after the end of the therapy.
  • CONCLUSION: Multiple applications of mitomycin C could be an effective treatment for selected cases of CCIN.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / therapeutic use. Neoplasms, Second Primary / drug therapy

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352093.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


8. Huerva V: [Topical interferon alfa-2b or surgical excision for primary treatment of conjunctiva-cornea intraepithelial neoplasia]. Arch Soc Esp Oftalmol; 2009 Jan;84(1):5-6
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical interferon alfa-2b or surgical excision for primary treatment of conjunctiva-cornea intraepithelial neoplasia].
  • [Transliterated title] Interferón alfa-2b tópico o escisión quirúrgica como tratamiento primario de la neoplasia conjuntival intraepitelial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Cryotherapy. Follow-Up Studies. Humans. Instillation, Drug. Ophthalmic Solutions. Postoperative Complications / prevention & control. Recombinant Proteins. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173133.001).
  • [ISSN] 1989-7286
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


9. Schechter BA, Koreishi AF, Karp CL, Feuer W: Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b. Ophthalmology; 2008 Aug;115(8):1291-6, 1296.e1
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b.
  • OBJECTIVE: To evaluate the long-term recurrence rate (>1 year) of conjunctival and corneal intraepithelial neoplasia (CIN) treated with topical interferon alfa-2b.
  • PARTICIPANTS: Twenty-eight eyes of 26 patients from 2 institutions, treated between April 1997 and June 2005, with CIN lesions utilized topical interferon alfa-2b drops 4 times daily until clinical resolution was achieved.
  • MAIN OUTCOME MEASURES: All eyes were monitored for the possibility of recurrence with a minimum of 1-year follow-up from the time of documented clinical resolution.
  • RESULTS: Complete clinical resolution of the CIN lesions was achieved in 27 of the 28 eyes treated (96.4%).
  • One of the 28 eyes treated (3.6%) had only a partial response to treatment.
  • Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in 3 patients (12%).
  • In all cases, there was total resolution of the side effects within 1 month after cessation of the medication.
  • CONCLUSIONS: In this group of patients with CIN lesions observed for >1 year, topical interferon alfa-2b was effective in treating lesions with minimal self-limited side effects.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Recombinant Proteins. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187195.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


10. Ballalai PL, Erwenne CM, Martins MC, Lowen MS, Barros JN: Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia. Ophthal Plast Reconstr Surg; 2009 Jul-Aug;25(4):296-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia.
  • PURPOSE: To evaluate the efficacy, recurrence rate, and long-term complications of topical mitomycin C (MMC) 0.02% for conjunctival-corneal intraepithelial neoplasia (CCIN).
  • METHODS: A prospective, nonrandomized, noncontrolled study was conducted of patients with primary or recurrent CCIN treated with topical MMC 0.02%, four times per day, for 28 consecutive days.
  • The main outcome measures were complete resolution of the neoplasia by slit-lamp examination and cytology 1 month after treatment, tumor recurrence, and long-term complications.
  • Complete resolution of the lesion was achieved in all patients after 1 month of treatment.
  • Recurrence occurred in 1 patient (4.3%) after 24 months of treatment.
  • Four patients developed corneal erosion (17.4%), 2 of them with primary CCIN and 2 with recurrent CCIN.
  • Corneal erosion occurred 4 to 24 months after treatment and was treated successfully.
  • The probability for corneal erosions by the log-rank test was equal for both groups (p = 0.1705).
  • Corneal erosion occurred in 17.4% of cases and can occur as late as 24 months after treatment.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Dose-Response Relationship, Drug. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Ophthalmic Solutions. Prospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617789.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


11. Dudney BW, Malecha MA: Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia. Am J Ophthalmol; 2004 May;137(5):950-1
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia.
  • PURPOSE: To report a case of conjunctival-corneal intraepithelial neoplasia (CCIN) in an elderly African American patient treated with topical mitomycin C and the subsequent complication of limbal stem cell deficiency.
  • RESULTS: The CCIN regressed completely following mitomycin C therapy.
  • Three months later, the patient developed recurrent nonhealing epithelial defects in the right cornea.
  • CONCLUSIONS: Conjunctival-corneal intraepithelial neoplasia may occur in the African American population.
  • Although MMC is effective in eradicating CCIN, a limbal stem cell deficiency may complicate the treatment.
  • [MeSH-major] Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / chemically induced. Corneal Diseases / drug therapy. Epithelium, Corneal / drug effects. Mitomycin / adverse effects. Stem Cells / drug effects
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / adverse effects. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Humans. Limbus Corneae / drug effects. Limbus Corneae / pathology. Recurrence

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15126170.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


12. Prabhasawat P, Tarinvorakup P, Tesavibul N, Uiprasertkul M, Kosrirukvongs P, Booranapong W, Srivannaboon S: Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea; 2005 May;24(4):443-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma.
  • PURPOSE: To demonstrate the efficacy of topical 0.002% mitomycin C (MMC) as an adjunctive and alternative treatment in primary and recurrent conjunctival-corneal intraepithelial neoplasia (CCIN) and squamous cell carcinoma (SCC).
  • All cases were treated with topical 0.002% MMC 4 times daily.
  • The tumor size pre- and post-treatment, clinical response, and ocular complications were evaluated.
  • Before MMC treatment, 6 eyes (85.7%) had recurrences after surgical excision.
  • MMC 0.002% 4 times daily was applied for a period of 5.4 +/- 4.4 weeks (range, 2-14).
  • Side effects of MMC therapy included ocular irritation, mild conjunctival hyperemia, and punctate keratopathy.
  • The mean follow-up time was 30.7 +/- 15 months (range, 2-52) with no evidence of clinical recurrence in any case.
  • CONCLUSIONS: Topical 0.002% MMC showed a favorable outcome as an adjunctive and alternative treatment of CCIN and SCC with regression of primary and recurrent tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma in Situ / drug therapy. Carcinoma, Squamous Cell / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15829803.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


13. Dogru M, Erturk H, Shimazaki J, Tsubota K, Gul M: Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia. Cornea; 2003 Oct;22(7):627-39
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia.
  • PURPOSE: To evaluate the tear function and ocular surface alterations in patients with primary CIN before and after treatment with topical mitomycin (MMC).
  • PATIENTS AND METHODS: We describe seven patients with unilateral CIN treated with 0.04% topical MMC three times daily until full eradication of the lesion.
  • The patients underwent tear and ocular surface examinations including Cochet-Bonnet corneal sensitivity measurements, tear film break-up time (BUT), Schirmer test, and Rose-Bengal staining before, at the time of resolution of the CIN, and at the final follow-up.
  • Conjunctival impression cytology was performed before treatment and at the last visit.
  • RESULTS: The mean pretreatment corneal sensitivity was 30.3 +/- 7.4 mm and improved to 55 +/- 5 mm at the final visit (P < 0.05).
  • MMC-induced cytologic changes were seen to persist long after cessation of treatment in some patients.
  • CONCLUSION: We found 0.04% topical MMC treatment tid until full eradication to be effective in the management of CIN.
  • The ocular surface disease of CIN was characterized by disturbance of tear film stability, goblet cell loss, and increased squamous metaplasia in all patients.
  • Impression cytology proved useful in attaining the diagnosis of CIN, evaluating the effect of treatment, and showing MMC-related long-term changes on the ocular surface.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Conjunctiva / pathology. Corneal Diseases / drug therapy. Corneal Diseases / pathology. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Mitomycin / administration & dosage. Tears / metabolism
  • [MeSH-minor] Administration, Topical. Aged. Cell Count. Cornea / physiopathology. Epithelial Cells / pathology. Female. Fluorescent Dyes. Goblet Cells / pathology. Humans. Male. Metaplasia. Middle Aged. Prospective Studies. Rose Bengal. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14508259.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Fluorescent Dyes; 1ZPG1ELY14 / Rose Bengal; 50SG953SK6 / Mitomycin
  •  go-up   go-down


14. Gabison EE, Labbé A, Brignole-Baudouin F, Nourry H, Putterman M, Malecaze F, Hoang-Xuan T, Baudouin C: Confocal biomicroscopy of corneal intraepithelial neoplasia regression following interferon alpha 2b treatment. Br J Ophthalmol; 2010 Jan;94(1):134-5
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal biomicroscopy of corneal intraepithelial neoplasia regression following interferon alpha 2b treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20385531.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


15. Singh AD, Jacques R, Rundle PA, Rennie IG, Mudhar HS, Slater D: Neoadjuvant topical mitomycin C chemotherapy for conjunctival and corneal intraepithelial neoplasia. Eye (Lond); 2006 Sep;20(9):1092-4
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant topical mitomycin C chemotherapy for conjunctival and corneal intraepithelial neoplasia.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Cornea / pathology. Mitomycin / therapeutic use
  • [MeSH-minor] Aged. Humans. Male. Neoadjuvant Therapy. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244642.001).
  • [ISSN] 0950-222X
  • [Journal-full-title] Eye (London, England)
  • [ISO-abbreviation] Eye (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


16. Díaz-Valle D, Benítez-del-Castillo JM, Díaz-Valle T, Poza-Morales Y, Arteaga-Sánchez A: [Treatment with topical interferon alone in severe conjunctivo-corneal neoplasia]. Arch Soc Esp Oftalmol; 2005 Dec;80(12):729-32
MedlinePlus Health Information. consumer health - Corneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment with topical interferon alone in severe conjunctivo-corneal neoplasia].
  • [Transliterated title] Interferón tópico como tratamiento único en un caso de neoplasia córneo-conjuntival severa.
  • The lesion was clinically diagnosed to be a conjunctival and corneal intraepithelial neoplasia (CIN).
  • Topical treatment with interferon alpha2b (INFalpha2b) four times daily was started and continued until the lesion had completely resolved at 4 months.
  • DISCUSSION: Topical INFalpha2b alone may be a safe and effective treatment of CIN instead of the other classic alternatives such as surgical excision with cryotherapy, which could induce the development of severe limbic deficiency in cases with extensive disease.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / administration & dosage
  • [MeSH-minor] Administration, Topical. Aged. Humans. Male. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16372217.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


17. Yeatts RP, Engelbrecht NE, Curry CD, Ford JG, Walter KA: 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology; 2000 Dec;107(12):2190-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea.
  • OBJECTIVE: To evaluate the efficacy of pulse dosing of topical 5-fluorouracil (5-FU) in the treatment of conjunctival and corneal intraepithelial neoplasia.
  • PARTICIPANTS: Seven patients with histologic evidence of intraepithelial neoplasia were identified by conjunctival biopsy or tumor excision.
  • Topical 1% 5-FU was administered four times daily for 2 to 4 days for each cycle.
  • The number of initial treatment cycles was two to six, with the time between cycles being 30 to 45 days.
  • MAIN OUTCOME MEASURES: The presence or absence of clinically evident intraepithelial neoplasia was evaluated after each treatment interval.
  • RESULTS: Four patients remain disease free with a mean follow-up of 18.5 months (range, 7-36 months) with no additional treatment after the initial treatment cycles (mean, 3.75 cycles; range, 2-5 cycles).
  • Three patients had recurrence of disease after the initial treatment cycles.
  • Two patients were treated with additional cycles for recurrent disease (six cycles in one patient and five cycles in the other patient) and are free of disease at 20 and 21 months after treatment, respectively.
  • One patient had persistent disease despite treatment with topical 5-FU and was treated with topical mitomycin C with resolution of the disease without recurrence for 16.5 months.
  • No adverse reactions to pulse dose treatment with topical 5-FU were noted.
  • CONCLUSIONS: Pulsed dosing with 1% topical 5-FU for the treatment of conjunctival and corneal intraepithelial neoplasia, alone or as an adjunct to excision of bulky disease, is a well-tolerated and effective method of treatment.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Fluorouracil / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Male. Ophthalmic Solutions / therapeutic use. Prospective Studies

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11097594.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Ophthalmic Solutions; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Rodríguez-Pérez C, Del Campo Z, Wolley-Dod C, Gris O: [Topical treatment with mitomycin C in considerably raised conjunctival intraepithelial neoplasia]. Arch Soc Esp Oftalmol; 2002 Dec;77(12):685-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical treatment with mitomycin C in considerably raised conjunctival intraepithelial neoplasia].
  • [Transliterated title] Tratamiento tópico con mitomicina C en la neoplasia intraepitelial córneo-conjuntival de gran espesor.
  • CASE REPORT: We present a case of recurrent conjunctival intraepithelial neoplasia, treated previously on two occasions with excisional biopsy.
  • Although the lesion was considerably raised, topical treatment with mitomycin-C 0.04% was applied, achieving the complete regression of the tumor.
  • However, successive treatment cycles can achieve complete regression, even in considerably thick tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Epithelium, Corneal / pathology. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12471516.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


19. Boehm MD, Huang AJ: Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology; 2004 Sep;111(9):1755-61
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
  • OBJECTIVE: To evaluate topical interferon alfa 2b (IFNalpha2b) as a single therapeutic agent in the treatment of presumed recurrent corneal and conjunctival intraepithelial neoplasia.
  • PARTICIPANTS: Seven consecutive patients with recurrent corneal and conjunctival intraepithelial neoplasia diagnosed at the University of Minnesota from July 2000 to November 2003 were studied retrospectively.
  • All patients had a history of histologically proven primary corneal and conjunctival intraepithelial neoplasia and were treated by surgery, cryotherapy, radiation, and/or topical mitomycin C before recurrence.
  • INTERVENTION: Patients with a clinical diagnosis of recurrent corneal and conjunctival intraepithelial neoplasia were treated with recombinant topical IFNalpha2b drops (1 million IU/ml) 4 times daily until lesion resolution was noted.
  • MAIN OUTCOME MEASURES: A review of medical records was performed to assess the duration of and response to treatment with topical IFNalpha2b, defined by clinical resolution of corneal and conjunctival intraepithelial neoplasia.
  • RESULTS: The average age of the 7 patients at the initiation of topical IFNalpha2b treatment for presumed recurrent corneal and conjunctival intraepithelial neoplasia was 68.7 years (range, 54-88).
  • Six of 7 patients had successful treatment of recurrent corneal and conjunctival intraepithelial neoplasia lesions with topical IFNalpha2b treatment.
  • The average length of IFNalpha2b treatment to resolution of recurrent corneal and conjunctival intraepithelial neoplasia was 14.5 weeks (range, 5-24).
  • After treatment with topical IFNalpha2b for recurrent corneal and conjunctival intraepithelial neoplasia, 2 patients had another recurrence of corneal and conjunctival intraepithelial neoplasia, noted at 1 year and 2 months, respectively.
  • The average post-treatment follow-up was 11.7 months (range, 8-17) after the resolution of recurrent corneal and conjunctival intraepithelial neoplasia.
  • No side effects of treatment were noted in any patient.
  • CONCLUSIONS: Topical IFNalpha2b as a single therapeutic agent is an effective treatment of presumed recurrent corneal and conjunctival intraepithelial neoplasia.
  • It offers the benefits of topical therapy and avoids the risks of surgical or other interventions-specifically, ocular surface toxicity, cicatricial conjunctival changes, and limbal stem cell deficiency.
  • Larger controlled studies with longer follow-up periods are recommended to confirm the long-term efficacy and safety of this topical treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Ophthalmic Solutions / administration & dosage. Ophthalmic Solutions / therapeutic use. Recombinant Proteins. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmology. 2005 Jul;112(7):1319; author reply 1319 [15993243.001]
  • (PMID = 15350333.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


20. Daniell M, Maini R, Tole D: Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Exp Ophthalmol; 2002 Apr;30(2):94-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia.
  • PURPOSE: To evaluate the efficacy of topical mitomycin C as a treatment of corneal conjunctival intraepithelial neoplasia.
  • METHODS: An open prospective analysis of 20 cases of corneal conjunctival intraepithelial neoplasia with recurrent disease (17 patients) or refusing surgery (three patients) were treated with topical mitomycin C.
  • Treatment was with mitomycin C eye drops, either 0.02% or 0.04%, four times daily for 1 week followed by a week off the cycle then repeated for a second week.
  • The mean time to resolution was 4.5 weeks, the mean number of cycles of treatment was two.
  • CONCLUSIONS: Mitomycin C is effective in inducing regression of corneal conjunctival intraepithelial neoplasia.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Eye Neoplasms / drug therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Ophthalmic Solutions. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11886411.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


21. Russell HC, Chadha V, Lockington D, Kemp EG: Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol; 2010 Oct;94(10):1316-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications.
  • INTRODUCTION: The use of topical mitomycin C (MMC) has gained popularity in the management of ocular surface neoplasia.
  • The aim of this study is to determine outcomes and complications following such treatment.
  • METHODS: This study is a retrospective review of patients treated with topical MMC for ocular surface neoplasia, including primary acquired melanosis (PAM), melanoma, corneal-conjunctival intraepithelial neoplasia (CCIN), squamous cell carcinoma (SCC) and sebaceous gland carcinoma (SGC).
  • Data regarding diagnosis, short- and long-term outcomes, and short- and long-term complications, were recorded.
  • 21 received MMC as primary therapy and 37 as surgical adjuvant.
  • The regimen was 0.04% MMC four times a day for 3 weeks on, 3 weeks off, 3 weeks on, with topical steroid and lubricants throughout.
  • Overall, 26% developed recurrent disease at a mean of 13 months post treatment.
  • Short-term complications occurred in 52%, but only 7% required treatment cessation.
  • Long-term complications such as persisting keratoconjunctivitis, epiphora and corneal problems, occurred in 31%.
  • CONCLUSION: The results confirm the effectiveness of topical MMC chemotherapy in the management of ocular surface neoplasia.
  • Self-limiting short-term complications were common; however, limbal stem cell deficiency appears to be a significant long-term complication of treatment, occurring in 12%.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Eye Neoplasms / drug therapy. Mitomycin / administration & dosage. Sebaceous Gland Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


22. Yamamoto N, Ohmura T, Suzuki H, Shirasawa H: Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C. Ophthalmology; 2002 Feb;109(2):249-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C.
  • PURPOSE: To describe the histopathological findings and successful treatment with 5-fluorouracil (5-FU) of a conjunctival intraepithelial neoplasia with limbal stem cell deficiency that was refractive to topical mitomycin-C (MMC).
  • INTERVENTION: A 64-year-old male patient presented with a diffuse conjunctival intraepithelial neoplasia (CIN) that was excised with concurrent keratoepithelioplasty.
  • Despite two courses of MMC, the tumor size did not decrease, and topical 5-FU was started 1 year after MMC therapy began.
  • RESULTS: After 5-FU treatment, the patient was free of the tumor clinically and cytologically, and the corneal surface had cleared.
  • No recurrence was observed during the 30 months after the 5-FU therapy.
  • CONCLUSIONS: Topical 5-FU may be a therapeutic option for the treatment of patients with MMC-resistant CINs.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Fluorouracil / therapeutic use. Mitomycin / therapeutic use
  • [MeSH-minor] Drug Resistance, Neoplasm. Epithelial Cells / transplantation. Humans. Limbus Corneae / cytology. Male. Middle Aged. Neoplasm Recurrence, Local. Stem Cell Transplantation. Transplantation, Autologous. Treatment Outcome

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthalmology. 2003 Jul;110(7):1289 [12867379.001]
  • [CommentIn] Ophthalmology. 2003 Apr;110(4):625-6; author reply 626 [12689863.001]
  • [CommentIn] Ophthalmology. 2003 Jun;110(6):1262-3; author reply 1263 [12799258.001]
  • (PMID = 11825803.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Zaki AA, Farid SF: Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up. Cornea; 2009 Oct;28(9):986-8
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intraepithelial and invasive neoplasia of the cornea and conjunctiva: a long-term follow up.
  • PURPOSE: The aim of this work is to report the long-term results of using immunotherapy for the management of cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma after surgical excision of the neoplasm.
  • METHODS: Ten eyes of 10 patients with cornea and conjunctiva intraepithelial neoplasia or squamous cell carcinoma had wide surgical excisions of the neoplasm after evaluation of the level of corneal involvement using ultrasound biomicroscopy.
  • All eyes received topical cyclosporine A (0.05%) and topical mitomycin C (0.01%) 4 times daily for 12 weeks after surgery.
  • Epithelial toxicity (punctate keratopathy) occurred in 3 eyes, ocular irritation and mild conjunctival hyperemia in 5 eyes, and lid toxicity in 2 cases during the treatment with mitomycin C.
  • There were no serious complications that necessitated stopping the treatment.
  • CONCLUSION: During a 2-year follow-up period, the use of topical cyclosporine A (0.05%) combined with mitomycin C (0.01%) as an adjunctive treatment after surgical excision in cornea and conjunctiva intraepithelial neoplasia and squamous cell carcinoma was found to prevent tumor recurrence, especially in extensive lesions, when surgical excision cannot ensure a tumor-free margin.
  • [MeSH-major] Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Conjunctival Neoplasms / therapy. Corneal Diseases / therapy. Eye Neoplasms / therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Cyclosporine / administration & dosage. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Mitomycin / administration & dosage. Neoplasm Invasiveness. Ophthalmologic Surgical Procedures. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cornea. 2012 Apr;31(4):465 [22314824.001]
  • [CommentIn] Cornea. 2011 Apr;30(4):486; author reply 486-7 [21107255.001]
  • (PMID = 19724215.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


24. Toledano Fernández N, García Sáenz S, Díaz Valle D, Arteaga Sánchez A, Segura Bedmar M, Lorenzo Giménez S, Cortés Lambea L: [Interferon alfa-2b treatment in selected cases of recurrent conjunctival intraepithelial neoplasia]. Arch Soc Esp Oftalmol; 2003 May;78(5):265-71
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interferon alfa-2b treatment in selected cases of recurrent conjunctival intraepithelial neoplasia].
  • [Transliterated title] Empleo de interferón alfa-2b para el tratamiento de carcinomas conjuntivales intraepiteliales en casos seleccionados.
  • PURPOSE: To study the efficacy of topical and combined topical and subconjunctival interferon alfa 2b (IFN alfa 2b) in the treatment of recurrent conjunctival intraepithelial neoplasia (CIN) in those patients who present resistance or intolerance to topical mitomycin C (MMC) treatment or when it is not indicated.
  • METHODS: Four patients (age range from 52 to 70) with histological confirmation of recurrent CIN were studied prospectively.
  • Two patients were resistant to topical MMC, another one did not tolerate it, and in the last case, this treatment was not indicated due to a stem cell insufficiency associated to a trophic corneal ulcer.
  • Three patients were given just topical interferon (1 million IU/ ml four times a day for three months), while the last one received topical therapy and subconjunctival IFN alfa 2b injections (3 millions IU/ 0.5 ml).
  • RESULTS: Complete regression of the tumour was evident in all cases. sixteen to 24 months after treatment no patient had clinical evidence of recurrence.
  • CONCLUSIONS: IFN alfa 2b is effective as an alternative treatment to topical MMC in selected cases of recurrent CIN.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Prospective Studies. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12789630.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


25. Ramos-López JF, Martínez-Costa Pérez R, Cisneros Lanuza AL, Francés Muñoz E, Monte Boque E, Muñoz Gómez MC, López-Sánchez EV, Menezo Rozalén JL: [Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%]. Arch Soc Esp Oftalmol; 2004 Aug;79(8):375-8
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%].
  • [Transliterated title] Tratamiento de las neoplasias conjuntivales intraepiteliales con colirio de mitomicina C al 0,02%
  • PURPOSE: To evaluate the efficacy of topical mitomycin C (MMC) 0.02% in treating conjunctival intraepithelial neoplasia (CIN).
  • METHODS: Three patients with CIN were treated with topical MMC 0.02%.
  • RESULTS: CIN was resolved in all three cases without modifying the normal corneal and conjunctival architecture.
  • CONCLUSIONS: Topical MMC 0.02% four times daily during two weeks is a useful alternative tool for the surgical management of CIN.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Mitomycin / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged. Humans. Male. Ophthalmic Solutions. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15306963.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Ophthalmic Solutions; 50SG953SK6 / Mitomycin
  •  go-up   go-down


26. Huerva V, Mateo AJ, Mangues I, Jurjo C: Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia. Cornea; 2006 Dec;25(10):1220-3
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term mitomycin C followed by long-term interferon alpha2beta for conjunctiva-cornea intraepithelial neoplasia.
  • PURPOSE: To report a case of extensive conjunctiva-cornea intraepithelial neoplasia (CIN) treated topically with mitomycin C (MMC) and interferon (INF)-alpha2beta without surgical resection.
  • RESULTS: : An 82-year-old woman showed an extensive gelatinous red mass in the bulbar conjunctiva with invasion into the caruncle, inferior fornix, and tarsal conjunctiva and extending for 270 degrees of the corneal surface.
  • A diagnosis of CIN was made by surgical biopsy.
  • A conservative treatment strategy was used with 2 cycles of topical MMC (0.02%), followed by INF-alpha2beta eye drops at a dose of 1 million IU/mL, 4 times a day until tumor disappearance.
  • Total resolution was noted after 75 days of treatment with INF, with no clinical evidence of limbal stem cell deficiency.
  • After 1 year of monitoring, no signs of CIN recurrences were observed.
  • CONCLUSION: MMC (0.02%), followed by INF-alpha2beta (1 million IU/mL) 4 times a day, is an effective treatment against highly extensive CIN, in cases where surgical resection with safety margins is unfeasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Biopsy. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Female. Humans. Interferon-alpha / administration & dosage. Mitomycin / administration & dosage. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172902.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


27. Di Pascuale MA, Espana EM, Tseng SC: A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles. Cornea; 2004 Jan;23(1):89-92
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles.
  • PURPOSE: To report a case of conjunctiva-cornea intraepithelial neoplasia (CCIN) treated with topical mitomycin C (MMC) and interferon alfa-2b in cycles.
  • The diagnosis was confirmed by impression cytology and treated in cycles with topical 0.02% MMC for 14 days in the first cycle, 12 days in the second cycle, and 3 days in the third cycle followed by topical interferon alfa-2b 1 x 106 U/mL for 11 days.
  • CONCLUSIONS: After differentiation from a persistent corneal epithelial defect and limbal stem cell deficiency by dye staining and impression cytology, the patient in this case of CCIN was successfully treated with topical MMC and interferon alfa-2b in cycles.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / administration & dosage. Mitomycin / administration & dosage
  • [MeSH-minor] Administration, Topical. Drug Administration Schedule. Female. Humans. Middle Aged. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14701965.001).
  • [ISSN] 0277-3740
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 50SG953SK6 / Mitomycin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


28. Huerva V, Sánchez MC, Mangues I: Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia. J Ocul Pharmacol Ther; 2007 Apr;23(2):143-5
MedlinePlus Health Information. consumer health - Corneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia.
  • AIMS: The aim of this study was to report on the effectiveness and tumor side effects of topical interferon (INF) alpha 2-beta in a case of conjunctiva-cornea intraepithelial neoplasia (CIN) of a patient that rejected any surgical procedure.
  • RESULTS: An 81-year-old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye.
  • Pathognomonic signs of CIN were present.
  • A regimen of topical INF alpha 2-beta 4 times daily was administered.
  • An increase in tumor volume of 25% was observable 15 days after the beginning of therapy.
  • The treatment continued with follow-ups every 15 days.
  • Complete regression of the CIN was observable after 60 days of therapy.
  • CONCLUSIONS: Topical INF alpha 2-beta is a valid choice for the treatment of CIN in patients for whom surgery is not possible.
  • The increase of tumor volume at the beginning of therapy does not require the suspension of treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Administration, Topical. Aged, 80 and over. Eye Neoplasms / drug therapy. Humans. Male. Ophthalmic Solutions. Recombinant Proteins. Remission Induction. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444802.001).
  • [ISSN] 1080-7683
  • [Journal-full-title] Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • [ISO-abbreviation] J Ocul Pharmacol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Ophthalmic Solutions; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


29. Fuchsluger TA, Hintschich C, Steuhl KP, Meller D: [Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface]. Ophthalmologe; 2006 Feb;103(2):124-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface].
  • [Transliterated title] Adjuvante topische Interferon-alpha-2b-Therapie bei epithelialen Tumoren der Augenoberfläche.
  • PURPOSE: The aim of this study was to evaluate the role of topical interferon-alpha-2b in the adjuvant treatment of corneal and conjunctival tumors.
  • METHOD: In this noncomparative, prospective, interventional case series, five patients with histologically proven conjunctival intraepithelial neoplasia (CIN) after primary excision and amniotic membrane transplantation were treated with interferon (IFN)-alpha-2b eye drops five times daily over a period of 6 weeks (1 million IU/ml Intron A, Schering).
  • RESULTS: In the follow-up period (13.2+/-4,97 months) no clinical evidence of recurrence with only limited treatment side effects such as mild conjunctival hyperemia were recorded after 6 weeks of interferon.
  • In one CIN specimen HPV 16/18 could be detected.
  • CONCLUSIONS: The combination of excisional biopsy and topical interferon-alpha-2b application seems to be an effective and safe treatment for conjunctival intraepithelial neoplasias.
  • Therefore, we prefer this combined treatment to topical interferon-alpha-2b treatment alone, more destructive approaches such as radiation and cryotherapy, or treatment with antimetabolites such as 5-fluorouracil or mitomycin C.
  • [MeSH-major] Conjunctival Neoplasms / drug therapy. Conjunctival Neoplasms / surgery. Epithelium, Corneal / drug effects. Epithelium, Corneal / surgery. Interferon-alpha / administration & dosage. Ophthalmologic Surgical Procedures / methods
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Female. Humans. Male. Middle Aged. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Soc Esp Oftalmol. 2003 May;78(5):265-71 [12789630.001]
  • [Cites] J Interferon Cytokine Res. 2000 Feb;20(2):143-51 [10714549.001]
  • [Cites] Am J Ophthalmol. 1972 Oct;74(4):688-93 [5075137.001]
  • [Cites] Cornea. 2004 Jan;23 (1):89-92 [14701965.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67 [13465720.001]
  • [Cites] Klin Monbl Augenheilkd. 1995 Oct;207(4):239-46 [8587298.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Ophthalmology. 1999 Jan;106(1):91-7 [9917787.001]
  • [Cites] Cornea. 1989;8(1):58-61 [2924586.001]
  • [Cites] Am J Ophthalmol. 2002 Aug;134(2):268-70 [12140037.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Am J Ophthalmol. 1989 Apr 15;107(4):337-40 [2929703.001]
  • [Cites] Refract Corneal Surg. 1993 Nov-Dec;9(6):443-51 [8117643.001]
  • [Cites] Ophthalmic Surg. 1990 Jan;21(1):27-30 [2325992.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):485-92 [9082277.001]
  • [Cites] Am J Ophthalmol. 1998 Jan;125(1):118-9 [9437331.001]
  • [Cites] Arch Ophthalmol. 1996 Mar;114(3):257-61 [8600883.001]
  • [Cites] Ophthalmology. 2001 Jun;108(6):1093-8 [11382635.001]
  • [Cites] Cornea. 1987;6(2):78-116 [3301209.001]
  • [Cites] Cornea. 2002 Jan;21(1):6-11 [11805499.001]
  • [Cites] Br J Ophthalmol. 2001 Jul;85(7):785-7 [11423448.001]
  • [Cites] JAMA. 1991 Sep 11;266(10):1375-83 [1715409.001]
  • [Cites] J Interferon Cytokine Res. 1999 Dec;19(12 ):1413-9 [10638710.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1777-9 [15150602.001]
  • [Cites] Ophthalmology. 1994 Feb;101(2):360-4 [8115157.001]
  • [Cites] Surgery. 2001 Nov;130(5):798-808 [11685189.001]
  • [Cites] J Lab Clin Med. 1995 Nov;126(5):474-84 [7595033.001]
  • [Cites] Radiother Oncol. 1990 Mar;17(3):191-7 [2320749.001]
  • [Cites] Arch Ophthalmol. 1994 Sep;112(9):1145-6 [8085957.001]
  • [Cites] Yan Ke Xue Bao. 1997 Mar;13(1):35-7 [11189324.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Jpn J Ophthalmol. 2002 Mar-Apr;46(2):215-7 [12062230.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):241-5 [1734085.001]
  • (PMID = 16047150.001).
  • [ISSN] 0941-293X
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 43K1W2T1M6 / interferon alfa-2b
  •  go-up   go-down


30. Schechter BA, Nagler RS, Schrier A: Recurrent intraepithelial neoplasia treatment. Ophthalmology; 2005 Jul;112(7):1319; author reply 1319
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent intraepithelial neoplasia treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma in Situ / drug therapy. Conjunctival Neoplasms / drug therapy. Corneal Diseases / drug therapy. Eye Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ophthalmology. 2004 Sep;111(9):1755-61 [15350333.001]
  • (PMID = 15993243.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down






Advertisement